Anaesthesia Primex Pharmaceuticals

Primex Pharmaceuticals:

The leading global
‘commercially focused’
Anaesthesia company

Portfolio Strategy 2021 - 2026


Launch OZALIN.

Expand geographically with established products: RECOFOL & OGNA.

Extend portfolio via new indications and acquisitions to strengthen ‘Triad’ of Anaesthesia.

Primex portfolio strategy

Existing Primex Product Portfolio

Recofol (propofol):

  • Recofol N – propofol with MCT/LCT formulation.
  • Recofol EDTA – propofol plus EDTA.
  • Propofo VET – propofol for animals.

OZALIN / OZASED* (2mg/ml oral midazolam solution):

  • ADV6209 was the former name of the product.
  • Licensed and approved for paediatric premedication and procedural sedation in the EU, UK and CH.

OGNA Dental Portfolio: 

  • Local Anaesthetic Portfolio – articaine, mepivicaine and lidocaine (spray & gel).
  • Endodontic Medical Devices (CE marked).